LGL Group (NYSEAMERICAN:LGL – Get Free Report) announced its quarterly earnings data on Friday. The industrial products company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.07), FiscalAI reports. LGL Group had a net margin of 1.66% and a return on equity of 0.16%. The company had revenue of $0.75 million during the quarter, compared to the consensus estimate of $0.80 million.
LGL Group Price Performance
LGL stock opened at $7.43 on Friday. LGL Group has a 1-year low of $5.45 and a 1-year high of $7.57. The stock has a market capitalization of $48.59 million, a P/E ratio of -185.75 and a beta of 0.32. The business has a fifty day moving average price of $6.96 and a 200-day moving average price of $7.06.
Analyst Ratings Changes
Separately, Zacks Research upgraded shares of LGL Group to a “hold” rating in a research report on Thursday, May 7th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat, the company has a consensus rating of “Hold”.
Institutional Trading of LGL Group
A hedge fund recently bought a new position in LGL Group stock. Citadel Advisors LLC purchased a new position in LGL Group, Inc. (The) (NYSEAMERICAN:LGL – Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 13,515 shares of the industrial products company’s stock, valued at approximately $90,000. Citadel Advisors LLC owned 0.25% of LGL Group as of its most recent SEC filing. 30.28% of the stock is currently owned by institutional investors and hedge funds.
About LGL Group
LGL Group Inc is a United States–based company specializing in the development and commercialization of digital pathology and molecular imaging systems for research and clinical laboratories. The company’s core focus lies in enabling high-resolution visualization and quantitative analysis of tissue samples, helping scientists and pathologists accelerate biomarker discovery and diagnostic workflows. LGL Group’s platform combines advanced optics, automated slide scanning and image analysis software to deliver end-to-end solutions tailored to oncology, immunology and neuroscience research.
The company’s flagship offerings include whole-slide scanners capable of rapid, high-throughput scanning at resolutions suited for detailed morphometric and fluorescence studies.
Further Reading
- Five stocks we like better than LGL Group
- 3 Unexpected ETFs Crushing the Market This Summer
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
Receive News & Ratings for LGL Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LGL Group and related companies with MarketBeat.com's FREE daily email newsletter.
